Source comparison
Sermorelin for Anti-Aging Doctors / Practitioners — Comparison
Sermorelin (200–500 mcg nightly) GHRH analog. Stimulates endogenous pulsatile GH release from the pituitary 30–50% above baseline within 8–12 weeks $150–$250 (including medication and supplies) Legal. Not a controlled substance; prescribed off-label under stan
This comparison does not assign a generated winner or score.
- Sermorelin (200–500 mcg nightly)
- GHRH analog. Stimulates endogenous pulsatile GH release from the pituitary
- 30–50% above baseline within 8–12 weeks
- $150–$250 (including medication and supplies)
- Legal. Not a controlled substance; prescribed off-label under standard medical practice
- Best option for most anti-aging protocols. Preserves endogenous feedback, lower side effect risk, sustainable cost
- Synthetic HGH (1–2 IU daily)
- Exogenous growth hormone. Bypasses pituitary, suppresses endogenous production
- 50–80% above baseline within 4–6 weeks
- $800–$1,500 (brand-name formulations)
- Restricted. DEA Schedule III; illegal to prescribe for anti-aging purposes outside approved indications
- Higher potency but unsustainable for most patients due to cost, side effects, and legal constraints
- GHRP-2 or Ipamorelin (100–300 mcg nightly)
- Ghrelin mimetic. Stimulates GH release via growth hormone secretagogue receptor
- 20–40% above baseline (less robust than sermorelin alone)
- $120–$200
- Legal. Similar regulatory standing as sermorelin
- Often combined with sermorelin for synergistic effect; less effective as monotherapy
- MK-677 (Ibutamoren, 10–25 mg oral daily)
- Oral ghrelin mimetic. Continuous GH elevation without pulsatility
- 30–60% above baseline (sustained elevation rather than pulsatile)
- $80–$150
- Legal. Not FDA-approved for any indication; sold as research compound
- Convenient oral dosing but disrupts natural pulsatility; may cause insulin resistance with prolonged use